Argos Therapeutics, Inc.
(Other OTC/NBB : ARGS)

( )
ARGS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.80%63.941.0%$481.30m
AMGNAmgen, Inc. -0.72%235.041.3%$433.22m
BIIBBiogen, Inc. -1.35%284.211.4%$384.69m
ILMNIllumina, Inc. -1.21%327.003.5%$329.26m
VRTXVertex Pharmaceuticals, Inc. -0.30%233.911.9%$282.39m
REGNRegeneron Pharmaceuticals, Inc. -0.71%356.602.6%$239.03m
EXASEXACT Sciences Corp. -2.93%92.1824.0%$232.61m
ALXNAlexion Pharmaceuticals, Inc. -2.56%108.552.0%$173.61m
INCYIncyte Corp. -0.31%78.242.5%$131.13m
AAgilent Technologies, Inc. -0.10%88.931.6%$126.88m
SRPTSarepta Therapeutics, Inc. -3.93%113.6814.6%$110.30m
BMRNBioMarin Pharmaceutical, Inc. -2.24%85.634.3%$107.80m
SGENSeattle Genetics, Inc. 3.27%115.356.1%$99.56m
BLUEbluebird bio, Inc. -4.35%89.7214.2%$89.98m
DERMDermira, Inc. -0.37%18.763.8%$83.55m

Company Profile

Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.